BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35361141)

  • 21. Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Suzuki Y; Kumada H
    Drug Des Devel Ther; 2014; 8():869-73. PubMed ID: 25061278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
    Kim YJ; Sinn DH; Gwak GY; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    World J Gastroenterol; 2012 Dec; 18(47):6996-7002. PubMed ID: 23322999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
    J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Park CH; Jung SW; Shin JW; Bae MA; Lee YI; Park YT; Chung HS; Park NH
    Clin Mol Hepatol; 2016 Mar; 22(1):152-9. PubMed ID: 27044766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B.
    Choe JY; Ko JS; Choe BH; Kim JE; Kang B; Lee KJ; Yang HR
    J Korean Med Sci; 2018 Jan; 33(2):e11. PubMed ID: 29215820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenofovir
    Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
    World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B.
    Lee S; Park JY; Kim D Y; Kim BK; Kim SU; Song K; Ku HJ; Han KH; Ahn SH
    J Med Virol; 2016 Jun; 88(6):1027-34. PubMed ID: 26538234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
    Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH
    Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
    Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
    BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.
    Srivastava M; Singh N; Dixit VK; Nath G; Jain AK
    Indian J Med Res; 2016 Sep; 144(3):424-432. PubMed ID: 28139541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance.
    Kim DY; Lee HW; Song JE; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
    J Med Virol; 2018 Mar; 90(3):497-502. PubMed ID: 29077211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults.
    Mokaya J; Maponga TG; McNaughton AL; Van Schalkwyk M; Hugo S; Singer JB; Sreenu VB; Bonsall D; de Cesare M; Andersson M; Gabriel S; Taljaard J; Barnes E; Preiser W; Van Rensburg C; Matthews PC
    J Clin Virol; 2020 Aug; 129():104548. PubMed ID: 32663786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of entecavir-based rescue therapy in lamivudine-resistant chronic hepatitis B patients in China: a retrospective study.
    Li W; Wang L; Liu Y; Li Y; Yu S
    Pharmazie; 2018 Apr; 73(4):223-247. PubMed ID: 29609690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Liu Y; Corsa AC; Buti M; Cathcart AL; Flaherty JF; Miller MD; Kitrinos KM; Marcellin P; Gane EJ
    J Viral Hepat; 2017 Jan; 24(1):68-74. PubMed ID: 27658343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Berg T; Marcellin P; Zoulim F; Moller B; Trinh H; Chan S; Suarez E; Lavocat F; Snow-Lampart A; Frederick D; Sorbel J; Borroto-Esoda K; Oldach D; Rousseau F
    Gastroenterology; 2010 Oct; 139(4):1207-17. PubMed ID: 20600025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
    Zoulim F; Białkowska-Warzecha J; Diculescu MM; Goldis AE; Heyne R; Mach T; Marcellin P; Petersen J; Simon K; Bendahmane S; Klauck I; Wasiak W; Janssen HL
    Hepatol Int; 2016 Sep; 10(5):779-88. PubMed ID: 27206517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
    Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature.
    Cho WH; Lee HJ; Bang KB; Kim SB; Song IH
    World J Gastroenterol; 2018 May; 24(17):1919-1924. PubMed ID: 29740207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
    Mello FC; Fernandes CA; Gomes Sde A
    Mem Inst Oswaldo Cruz; 2012 May; 107(3):317-25. PubMed ID: 22510826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.